Figure 2.

CAF-CM promotes non-small cell lung cancer cell resistance to cisplatin. (A) MTT assay was conducted to detect cell viability at 0, 24, 48 and 72 h in A549 and H1299 cells pre-treated with CAF-CM or NF-CM for 24 h before the treatment of DDP. (B) Flow cytometry analysis was used to assess apoptosis of A549 and H1299 cells pre-treated with CAF-CM or NF-CM for 24 h before the treatment of DDP. Results were expressed as the mean ± SD, and the means were calculated from ≥3 independent experiments. **P<0.01, ***P<0.001 and ****P<0.0001 vs. control. CAF, cancer-associated fibroblast; NF, normal fibroblast; CM, conditioned medium; DDP, cisplatin; OD, optical density.